Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
CA 2522331 C · Owner: Protein Design Labs, Inc. · Inventors: Hinton, Paul R.; Vasquez, Maximiliano; Tso, J. Yun
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides for a modified antibody of class IgG in which , at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250 314, and 428 is substituted with , another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum halflife in comparison to the unmodified antibody.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 9, 2004 and granted November 12, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 9, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 9, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.